Acumen Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ABOS Nasdaq 2836 acumenpharm.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference - Sep 30th, 2024 8:00 pm
Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s Disease - Sep 26th, 2024 12:00 pm
Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024 - Sep 25th, 2024 8:00 pm
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference - Sep 3rd, 2024 8:00 pm
Q2 2024 Acumen Pharmaceuticals Inc Earnings Call - Aug 14th, 2024 3:26 am
Acumen Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Highlights - Aug 13th, 2024 11:00 am
Acumen Pharmaceuticals to Report Second Quarter Results on August 13, 2024 - Aug 6th, 2024 8:00 pm
Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer’s Disease - Jul 29th, 2024 11:00 am
Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024 - Jul 28th, 2024 11:30 am
Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024 - Jul 11th, 2024 12:00 pm
Is Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) the Best Halal Stock According to Hedge Funds? - Jun 21st, 2024 3:13 pm
Acumen Pharmaceuticals Inc (ABOS) (Q1 2024) Earnings Call Transcript Highlights: Strategic ... - May 15th, 2024 7:00 am
Q1 2024 Acumen Pharmaceuticals Inc Earnings Call - May 15th, 2024 6:06 am
Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights - May 14th, 2024 11:00 am
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference - May 13th, 2024 8:00 pm
Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference - May 8th, 2024 9:47 pm
Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease - May 8th, 2024 12:00 pm
Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024 - May 7th, 2024 8:00 pm
12 Cheap Foods With Anti-Aging Properties That Longevity Scientists Swear By - Apr 19th, 2024 4:13 pm
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting - Apr 16th, 2024 12:00 pm